H.C. Wainwright lowered the firm’s price target on Coherus Biosciences to $13 from $20 and keeps a Buy rating on the shares. The anlayst is taking a more conservative view on toripalimab’s launch into new indications.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CHRS:
- Coherus Biosciences reports Q3 EPS (27c), consensus (31c)
- Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
- CHRS Earnings this Week: How Will it Perform?
- Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
- Coherus Biosciences presents data from next-generation immuno-oncology programs